高聚金葡素联合博来霉素胸腔内注射治疗恶性胸腔积液82例临床研究  

Clinical study of highly agglutinative staphylococcin combining with bleomycin by intrapleural injection in the treatment of malignant pleural effusion in 82 cases

作　　者：翁冠裕 

机构地区：[1]江西省广丰县人民医院内科,江西广丰334600

出　　处：《中国当代医药》2013年第29期82-83,共2页China Modern Medicine

摘　　要：目的 分析和研究高聚金葡素联合博来霉素胸腔内注射治疗恶性胸腔积液的临床效果.方法 选取2010年2月～2012年2月本院收治的恶性胸腔积液患者82例,按双盲随机方法分为对照组41例与观察组41例.对照组患者在全身化疗基础上加用博来霉素给予胸腔内注射治疗;观察组患者在全身化疗基础上加用高聚金葡素与博来霉素胸腔注射治疗.比较两组患者治疗后的效果.结果 观察组患者治疗总有效率明显高于对照组,差异有统计学意义（P＜0.05）.观察组患者治疗期间的不良反应发生例数明显低于对照组,差异有统计学意义（P＜0.05）.结论 高聚金葡素联合博来霉素治疗恶性胸腔积液,治疗效果明显,能够减少化疗药物引起的骨髓抑制与胃肠道的毒副反应,安全性较高,有效提高了患者的生活质量,值得临床应用与推广.Objective To analyze and study the clinical effect of highly agglutinative staphylococcin （HAS） combining with bleomycin by intrapleural injection in the treatment of malignant pleural effusion （MPE）. Methods 82 patients with MPE admitted into our hospital from February 2010 to February 2012 and evenly divided into control group in 41 cases and observation group in 41 cases by randomized,double blind method.In the control group,on the basis of systemic ehemotherapy,bleomycin was given by intrapleural injection.In the observation group,on the basis of systemic chemotherapy,HAS combining with bleomyein was additionally applied by intrapleural injection.The effects after treat- ment in both groups were compared. Results The total effective rate in the observation group was obviously higher than that in the control group with a statistical difference （P〈0.05）iCases of adverse reaction during treatment in the observation group were fewer in comparison with the control group,which clisplayed a statistical difference （P〈0.05）. Conclusion Combination of HAS and bleomycin in high safety can obtain a remarkable effect on treating MPE.It can reduce toxic and side effects of myelosuppression and gastrointestinal tract triggered by chemotherapy drug and effective- ly improve patient＇s quality of life,which is worthy of application and expansion in clinic.

关 键 词：恶性胸腔积液 高聚金葡素 博来霉素 治疗效果 

分 类 号：R561.3[医药卫生—呼吸系统]